Login
NextCure, Inc. logo

NextCure, Inc.

nextcure.com

What Do They Do?

Develops targeted cancer medicines, including antibody-drug conjugates, for patients with solid tumors such as ovarian, breast and endometrial cancers.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +21% (Loss)
vs −$8.6M in Q3 FY2025
  • Nov 10, 2026 NextCure advances proposed merger with Avere and transfers LNCB74 development Approximately $820 million of financing is committed; LigaChem took over LNCB74 development, while NextCure retains potential milestone and royalty rights.

From immune discovery to ADC development The older report described an immune-focused discovery platform and immunomedicine pipeline; the latest centers development on antibody-drug conjugates for cancer.

Earlier programs move toward partnering The older report described active development of clinical oncology programs; the latest says NextCure is seeking partners for those programs.

Who Do They Compete With?

Competes with Merck &, Daiichi Sankyo, OnCusp Therapeutics, Hansoh Pharma, AbbVie, Genmab, AstraZeneca, BeiGene, GSK, and Day One Biopharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support